Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021;39:1485–505. https://doi.org/10.1200/jco.20.03399.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, et al. Association of event-free and distant recurrence-free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer: three-year follow-up analysis for the I-SPY2 adaptively randomized clinical trial. JAMA Oncol. 2020;6:1355–62. https://doi.org/10.1001/jamaoncol.2020.2535.

Article  PubMed  PubMed Central  Google Scholar 

Conforti F, Pala L, Sala I, Oriecuia C, De Pas T, Specchia C, et al. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. BMJ (Clinical Res ed). 2021;375:e066381. https://doi.org/10.1136/bmj-2021-066381.

Article  Google Scholar 

Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164–72. https://doi.org/10.1016/s0140-6736(13)62422-8.

Article  PubMed  Google Scholar 

Zhang M, Rosen JM. Developmental insights into breast cancer intratumoral heterogeneity. Trends Cancer. 2015;1:242–51. https://doi.org/10.1016/j.trecan.2015.10.005.

Article  PubMed  PubMed Central  Google Scholar 

Brooks MD, Burness ML, Wicha MS. Therapeutic implications of cellular heterogeneity and plasticity in breast cancer. Cell Stem Cell. 2015;17:260–71. https://doi.org/10.1016/j.stem.2015.08.014.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wu J, Cao G, Sun X, Lee J, Rubin DL, Napel S, et al. Intratumoral spatial heterogeneity at perfusion MR imaging predicts recurrence-free survival in locally advanced breast cancer treated with neoadjuvant chemotherapy. Radiology. 2018;288:26–35. https://doi.org/10.1148/radiol.2018172462.

Article  PubMed  PubMed Central  Google Scholar 

Huang K, Wu Y, Xie Y, Huang L, Liu H. Analyzing mRNAsi-related genes identifies novel prognostic markers and potential drug combination for patients with basal breast cancer. Dis Markers. 2021;2021:4731349. https://doi.org/10.1155/2021/4731349.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhang M, Tsimelzon A, Chang CH, Fan C, Wolff A, Perou CM, et al. Intratumoral heterogeneity in a Trp53-null mouse model of human breast cancer. Cancer Discov. 2015;5:520–33. https://doi.org/10.1158/2159-8290.cd-14-1101.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lyman GH, Greenlee H, Bohlke K, Bao T, DeMichele AM, Deng GE, et al. Integrative therapies during and after breast cancer treatment: ASCO endorsement of the SIO clinical practice guideline. J Clin Oncol. 2018;36:2647–55. https://doi.org/10.1200/jco.2018.79.2721.

Article  PubMed  CAS  Google Scholar 

Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G, Van Loo P, et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med. 2015;21:751–9. https://doi.org/10.1038/nm.3886.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70. https://doi.org/10.1038/nature11412.

Article  CAS  Google Scholar 

Mirón Mombiela R, Arildskov AR, Bruun FJ, Hasselbalch LH, Holst KB, Rasmussen SH, et al. What genetics can do for oncological imaging: a systematic review of the genetic validation data used in radiomics studies. Int J Mol Sci. 2022. https://doi.org/10.3390/ijms23126504.

Article  PubMed  PubMed Central  Google Scholar 

O’Connor JP, Rose CJ, Waterton JC, Carano RA, Parker GJ, Jackson A. Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical outcome. Clin Cancer Research: Official J Am Association Cancer Res. 2015;21:249–57. https://doi.org/10.1158/1078-0432.ccr-14-0990.

Article  Google Scholar 

Han S, Choi JY. Prognostic value of (18)F-FDG PET and PET/CT for assessment of treatment response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. Breast Cancer Res. 2020;22:119. https://doi.org/10.1186/s13058-020-01350-2.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Seban RD, Arnaud E, Loirat D, Cabel L, Cottu P, Djerroudi L, et al. [18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab. Eur J Nucl Med Mol Imaging. 2023;50:4024–35. https://doi.org/10.1007/s00259-023-06394-y.

Article  PubMed  CAS  Google Scholar 

Antunovic L, De Sanctis R, Cozzi L, Kirienko M, Sagona A, Torrisi R, et al. PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2019;46:1468–77. https://doi.org/10.1007/s00259-019-04313-8.

Article  PubMed  Google Scholar 

Li H, Yao L, Jin P, Hu L, Li X, Guo T, et al. MRI and PET/CT for evaluation of the pathological response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. Breast. 2018;40:106–15. https://doi.org/10.1016/j.breast.2018.04.018.

Article  PubMed  Google Scholar 

Gao Y, Fu Z, Zhu X, Li H, Yin L, Wu C, et al. Metabolic characterization and radiomics-based composite model for breast cancer immune microenvironment types using (18)F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2025. https://doi.org/10.1007/s00259-025-07306-y.

Article  PubMed  PubMed Central  Google Scholar 

Hirakata T, Fujii T, Kurozumi S, Katayama A, Honda C, Yanai K, et al. FDG uptake reflects breast cancer immunological features: the PD-L1 expression and degree of TILs in primary breast cancer. Breast Cancer Res Treat. 2020;181:331–8. https://doi.org/10.1007/s10549-020-05619-0.

Article  PubMed  CAS  Google Scholar 

Huang J, Huang L, Zhou J, Duan Y, Zhang Z, Wang X, et al. Elevated tumor-to-liver uptake ratio (TLR) from (18)F-FDG-PET/CT predicts poor prognosis in stage IIA colorectal cancer following curative resection. Eur J Nucl Med Mol Imaging. 2017;44:1958–68. https://doi.org/10.1007/s00259-017-3779-0.

Article  PubMed  PubMed Central  Google Scholar 

Chen K, Wang J, Li S, Zhou W, Xu W. Predictive value of (18)F-FDG PET/CT-based radiomics model for neoadjuvant chemotherapy efficacy in breast cancer: a multi-scanner/center study with external validation. Eur J Nucl Med Mol Imaging. 2023;50:1869–80. https://doi.org/10.1007/s00259-023-06150-2.

Article  PubMed  CAS  Google Scholar 

Goodyear MD, Krleza-Jeric K, Lemmens T. The Declaration of Helsinki. BMJ. 2007;335:624–5. https://doi.org/10.1136/bmj.39339.610000.BE.

Article  PubMed  PubMed Central  Google Scholar 

Burstein HJ, Curigliano G, Thürlimann B, Weber WP, Poortmans P, Regan MM, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021;32:1216–35. https://doi.org/10.1016/j.annonc.2021.06.023.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Li J, Jiang Z. Chinese society of clinical oncology breast cancer (CSCO BC) guidelines in 2024: international contributions from China. Cancer Biol Med. 2024;21:838–43. https://doi.org/10.20892/j.issn.2095-3941.2024.0374.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, et al. Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22:331–57. https://doi.org/10.6004/jnccn.2024.0035.

Article  PubMed  CAS  Google Scholar 

Hatzioannou A, Nayar S, Gaitanis A, Barone F, Anagnostopoulos C, Verginis P. Intratumoral accumulation of podoplanin-expressing lymph node stromal cells promote tumor growth through elimination of CD4(+) tumor-infiltrating lymphocytes. Oncoimmunology. 2016;5:e1216289. https://doi.org/10.1080/2162402x.2016.1216289.

Article